Screener
PTC Therapeutics PTCT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $2,869,104 | $2,898,767 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $313,050 | $381,272 |
| Current portion of long-term debt | 286,937 | 286,631 |
| Deferred revenue | 498 | 2,040 |
| Operating lease liabilities- current | 12,078 | 12,484 |
| Finance lease liabilities- current | 6,000 | 3,000 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's accounts payable?
- PTC Therapeutics (PTCT) reported accounts payable of $313.05M in Q1 2026.
- How has PTC Therapeutics's accounts payable changed year-over-year?
- PTC Therapeutics's accounts payable decreased by 1.5% year-over-year, from $317.81M to $313.05M.
- What is the long-term trend for PTC Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), PTC Therapeutics's accounts payable has grown at a 9.5% compound annual growth rate (CAGR), from $242.17M to $381.27M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about PTC Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude